DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

New research linking dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes to an increased risk for inflammatory bowel disease (IBD) is prompting investigators to urge monitoring of ...

They work by blocking the DPP-4 enzyme that is involved in the body's inflammatory response and regulates gut hormones. Some data suggest that lower serum levels of DPP-4 enzyme may be linked to ...

Please provide your email address to receive an email when new articles are posted on . Patients who took dipeptidyl peptidase-4 inhibitors — an increasingly common second-line treatment for type 2 ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

San Diego, Calif. - April 20, 2010 - Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy ...